It is presumed that in 2024 there will be a biological variant that will infect children. According to historical biological clock. Did you know? Héctor Damián Brzostowski CEO
It is presumed that in 2024 there will be a biological variant that will infect children. According to historical biological clock. Did you know? Héctor Damián Brzostowski CEO
Few want to talk about these possibilities but returning to history in the year 1624, 1724, 1824, 1924 and 2024 is expected...
Research Summary:
African swine fever that will transfer to the human host (ASF) is a devastating disease that affects both wild boar and domestic pigs. An outbreak in the Caucasus in 2007 began to spread through Russia and Eastern Europe, currently affecting Ukraine, Belarus, Poland, the Baltic States, the Czech Republic, Hungary, Moldova, Bulgaria and Romania. In August 2018, outbreaks were reported in Belgium and China, representing dramatic extensions of the geographic distribution of African swine fever and further elevating the threat to the global swine industry. This situation makes it imperative to improve our knowledge to make defensive tools against this important pathogen. The ASFV genome encodes many genes that are not essential for virus replication but are known to control host immune evasion, such as NFκB and the NFAT regulator A238L, the apoptosis inhibitor A224L, the viral homologue of cellular CD2 , which mediates hemadsorption, and AP-1. regulation, and several genes that modulate IFN synthesis in the infected cell. It is assumed that these genes are involved in the natural attenuation of the NH/P68 of the parental genotype I ASFV. Currently, our group is devoting efforts to construct live attenuated vaccine (LAV) prototypes, by constructing recombinant viruses of both the NH/ P68 naturally attenuated as virulent, currently circulating in Europe and China Armenia/07. The recombinant prototypes, the naturally attenuated and modified ASFV strain NH/P68 produced in porcine alveolar macrophages (PAM), were used to vaccinate pigs protected against the homologous (genotype I) Lisbon 60 (L60) and the heterologous Armenia/ 07 (genotype II). All recombinant viruses carrying specific deletions were fully protective against the parental L60 and only slightly protective against the circulating heterologous strain Armenia07. Furthermore, our results suggested that, in addition to the viral abilities acting to evade the immune system, the lack of protection should probably be related to the cell line used to generate the vaccine; therefore, identify a bottleneck that will compromise safe commercial production of effective LAVs. In this regard, we have recently established several cell lines that can potentially be used to produce live African swine fever virus vaccines. And your country already has the vaccine ready to protect your children. Or will it say again... It took us by surprise it's hard to know how it works...
As always, Argentina is a country of scientists... They are already working on this matter... https://fb.watch/gpMz5a2Zuq/
Comentarios
Publicar un comentario